Company Website:
http://www.oncosec.com
SAN DIEGO -- (Business Wire)
The date in the second paragraph, second sentence should read Wednesday,
March 11th (instead of Wednesday, March 8th).
The corrected release reads:
ONCOSEC MEDICAL TO PRESENT AT PROMINENT SCIENTIFIC AND INVESTMENT
CONFERENCES IN MARCH
OncoSec Medical Inc. (OTCQB: ONCS),
a company developing DNA-based intratumoral cancer immunotherapies,
announced today that it will present at several high-profile events in
March, including the 27th Annual ROTH Conference and the 5th
Annual "Cancer Immunotherapy: A Long- Awaited Reality" Conference.
27th Annual ROTH Conference
Punit Dhillon, President and CEO, will present a corporate overview at
the 27th Annual ROTH Conference, which is held March 8-11 in
Dana Point, CA. The presentation is scheduled to begin at 8:00 AM PT on
Wednesday, March 11th in the Colonnade Room on Track 4.
Each year, the ROTH Conference gathers institutional investors, private
equity investors, company executives and service providers to build
relationships and provide a platform for networking with existing and
potential clients. The conference features presentations from hundreds
of public and private companies in a variety of sectors, including
healthcare, business services, consumer, and industrial growth. For more
information, please visit: http://www.roth.com.
OncoSec invites investors and the general public to view and listen to
the live webcast. At the time of the presentation, the webcast will be
available via the following link: http://wsw.com/webcast/roth29/oncs.
Please register at least 10 minutes prior to the start of the
presentation to ensure timely access. After the presentation, an
archived version of the webcast will be available for 90 days on
OncoSec’s website: http://www.oncosec.com.
5th Annual "Cancer Immunotherapy: A Long-
Awaited Reality" Conference
Robert H. Pierce, MD, Chief Scientific Officer, will present a corporate
overview as well as a lecture, entitled: "Taking the Fight to the Tumor:
A Rationale for Intratumoral Electroporation of Immunomodulators” at
MaidStone Life Sciences’ 5th Annual "Cancer Immunotherapy: A
Long-Awaited Reality" Conference on Thursday, March 26th
at the New York Academy of Medicine in New York City. Dr. Pierce will
also join key opinion leaders to discuss the role of cancer vaccines in
a panel discussion, entitled "What Is the Role of Cancer Vaccines in an
Environment Overwhelmed by Checkpoint Inhibitors and T-Cell
Immunotherapies?”
The annual "Cancer Immunotherapy: A Long-Awaited Reality" is a
single-day conference that unites founding visionary researchers,
clinicians, business leaders, key investors, and other stakeholders to
engage in discussions and showcase leading companies in the field of
cancer immunotherapy. The conference format is designed to foster
networking, knowledge sharing, and learning in an interactive
environment. For more information, please visit: http://www.maidstonels.com/conference.html.
About OncoSec Medical
OncoSec Medical Inc. is a biopharmaceutical company developing its
investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec
Medical's core technology is designed to enhance the local delivery and
uptake of DNA IL-12 and other DNA-based immune-targeting agents.
Clinical studies of ImmunoPulse have demonstrated an acceptable safety
profile and preliminary evidence of anti-tumor activity in the treatment
of various skin cancers, as well as the potential to initiate a systemic
immune response limiting the systemic toxicities associated with other
treatments. OncoSec's lead program evaluating ImmunoPulse for the
treatment of metastatic melanoma is currently in Phase II development,
and is being conducted in collaboration with several prominent academic
medical centers. As the company continues to evaluate ImmunoPulse in its
current indications, it is also focused on identifying and developing
new immune-targeting agents, investigating additional tumor indications,
and evaluating combination-based immunotherapy approaches. For more
information, please visit www.oncosec.com.
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Any statements in this release that are not historical facts may be
considered such “forward-looking statements.” Forward-looking statements
are based on management’s current preliminary expectations and are
subject to risks and uncertainties, which may cause our results to
differ materially and adversely from the statements contained herein.
Some of the potential risks and uncertainties that could cause actual
results to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or commercialize new
products, uncertainties inherent in pre-clinical studies and clinical
trials, unexpected new data, safety and technical issues, competition,
and market conditions. These and additional risks and uncertainties are
more fully described in OncoSec Medical’s filings with the Securities
and Exchange Commission. Undue reliance should not be placed on
forward-looking statements, which speak only as of the date they are
made. OncoSec Medical disclaims any obligation to update any
forward-looking statements to reflect new information, events or
circumstances after the date they are made, or to reflect the occurrence
of unanticipated events.
Contacts:
OncoSec Medical Inc.
Investor Relations:
Jordyn Kopin,
855-662-6732
investors@oncosec.com
or
Media
Relations:
Mary Marolla, 855-662-6732
media@oncosec.com
Source: OncoSec Medical Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.